Cargando…
Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database
Serum insulin-like growth factor-1 (IGF-I) and IGF binding protein-3 (IGFBP-3) levels can be used to monitor the safety of recombinant human growth hormone (rhGH) therapy. In this study, we evaluated the changes in serum IGF-I and IGFBP-3 levels during rhGH therapy as a marker of height outcome in p...
Autores principales: | Kim, Minsun, Kim, Eun Young, So, Cheol Hwan, Kim, Chan Jong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559946/ https://www.ncbi.nlm.nih.gov/pubmed/34723984 http://dx.doi.org/10.1371/journal.pone.0259287 |
Ejemplares similares
-
Corroboration of Height Velocity Prediction Markers for rhGH With an Oral GH Secretagogue Treatment in Children With GHD
por: Blum, Werner F, et al.
Publicado: (2021) -
Inside the Noonan “universe”: Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns
por: Stagi, Stefano, et al.
Publicado: (2022) -
Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1
por: Felício, João Soares, et al.
Publicado: (2019) -
Noonan syndrome: rhGH treatment and
PTPN11
mutation
por: Wu, Xian, et al.
Publicado: (2023) -
GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy
por: Savage, Martin O., et al.
Publicado: (2021)